PharmaEngine
4162.TWO
2.79 USD
0.09
+3.33%
p
Overview
Last close
2.79 usd
Market cap
400.53M usd
52 week high
3.68 usd
52 week low
2.32 usd
Target price
3.7 usd
Valuation
P/E
7.2227
Forward P/E
N/A
Price/Sales
5.136
Price/Book Value
2.3388
Enterprise Value
270.35M usd
EV/Revenue
3.4778
EV/EBITDA
4.0394
Key financials
Revenue TTM
77.74M usd
Gross Profit TTM
76.27M usd
EBITDA TTM
63.30M usd
Earnings per Share
0.37 usd
Dividend
0.18 usd
Total assets
178.36M usd
Net debt
N/A usd
About
PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan.
- Symbol4162.TWO
- ExchangeTWO
- IsinTW0004162003
- CountryTaiwan
- SectorHealthcare
- IndustryBiotechnology
- CEOMr. Hong-Ren Wang Ph.D.
- HeadquarterTaipei
- Web sitehttps://www.pharmaengine.com
